Prolonged protection against intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant

Clinical and Vaccine Immunology

Volumn 16, Issue 4, 2009, Pages 471-478

  Zhou, Fengmin ^a   Goodsell, Amanda ^a   Uematsu, Yasushi ^b   Vajdy, Michael ^a,c  

^a Novartis Vaccines and Diagnostics Inc   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c EpitoGenesis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BACTERIAL TOXIN; CYTOKINE; HEMAGGLUTININ; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; LTK63 TOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HEAT; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; LETHAL DOSE; MORBIDITY; MORTALITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; VIRUS MUTANT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL TOXINS; BODY WEIGHT; CYTOKINES; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI PROTEINS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS;

EID: 64549126021     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00311-08     Document Type: Article

References (65)

1. Ambrose, C. S., R. E. Walker, and E. M. Connor. 2006. Live attenuated influenza vaccines in children. Semin. Pediatr. Infect. Dis. 17:206-212.
2. Anjuere, F., A. George-Chandy, F. Audant, D. Rousseau, J. Holmgren, and C. Czerkinsky. 2003. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J. Immunol. 170:1586-1592.
3. Arulanandam, B. P., R. H. Raeder, J. G. Nedrud, D. J. Bucher, J. Le, and D. W. Metzger. 2001. IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J. Immunol. 166:226-231.
4. Asahi-Ozaki, Y., T. Yoshikawa, Y. Iwakura, Y. Suzuki, S. Tamura, T. Kurata, et al. 2004. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J. Med. Virol. 74:328-335.
5. Asahi, Y., T. Yoshikawa, I. Watanabe, T. Iwasaki, H. Hasegawa, Y. Sato, et al. 2002. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol. 168:2930-2938.
6. Asanuma, H., F. Koide, Y. Suzuki, T. Nagamine, C. Aizawa, T. Kurata, et al. 1995. Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration. Vaccine 13:3-5.
7. Barnett, S. W., I. K. Srivastava, F. E. Kan, F. Zhou, A. Goodsell, A. D. Cristillo, et al. 2008. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22:339-348.
8. Belshe, R., M. S. Lee, R. E. Walker, J. Stoddard, and P. M. Mendelman. 2004. Safety, immunogenicity, and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines 3:643-654.
9. Belshe, R. B., W. C. Gruber, P. M. Mendelman, H. B. Mehta, K. Mahmood, K. Reisinger, et al. 2000. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181:1133-1137.
10. Bender, B. S., M. P. Johnson, and P. A. Small. 1991. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology 72:514-519.
11. Bizanov, G., L. Janakova, S. E. Knapstad, T. Karlstad, H. Bakke, I. L. Haugen, et al. 2005. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness. Scand. J. Immunol. 61:503-510.
12. Brandtzaeg, P. 2003. Role of mucosal immunity in influenza. Dev. Biol. 115:39-48.
13. Brown, T. A., B. R. Murphy, J. Radl, J. J. Haaijman, and J. Mestecky. 1985. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J. Clin. Microbiol. 22:259-264.
14. Chen, Z. M., J. H. Mao, L. Z. Du, and Y. M. Tang. 2002. Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection. Acta Paediatr. 91:914-922.
15. Clements, M. L., and I. Stephens. 1997. New and improved vaccines against influenza, p. 545-570. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines, 2nd ed. Marcel Dekker, Inc., New York, NY.
16. Connell, T. D., D. Metzger, C. Sfintescu, and R. T. Evans. 1998. Immunostimulatory activity of LT-IIa, a type II heat-labile enterotoxin of Escherichia coli. Immunol. Lett. 62:117-120.
17. Daniele, R. P. 1990. Immunoglobulin secretion in the airways. Annu. Rev. Physiol. 52:177-195.
18. de Haan, A., H. J. Geerligs, J. P. Huchshorn, G. J. van Scharrenburg, A. M. Palache, and J. Wilschut. 1995. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13:155-162.
19. El-Kady, I. M., M. Lotfy, G. Badra, S. El-Masry, and I. Waked. 2005. Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. Scand. J. Immunol. 61:87-91.
20. Fan, X. G., W. E. Liu, C. Z. Li, Z. C. Wang, L. X. Luo, D. M. Tan, et al. 1998. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediators Inflamm. 7:295-297.
21. Gallichan, W. S., and K. L. Rosenthal. 1996. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 184:1879-1890.
22. Ghendon, Y. 1989. The immune response of humans to live and inactivated influenza vaccines. Adv. Exp. Med. Biol. 257:37-45.
23. Glezen, W. P. 1982. Serious morbidity and mortality associated with influenza epidemics. Epidemiol. Rev. 4:25-14.
24. Goodsell, A., F. Zhou, S. Gupta, M. Singh, P. Malyala, J. Kazzaz, et al. 2007. β7-Integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology 123:378-389.
25. Haan, L., W. R. Verweij, M. Holtrop, R. Brands, G. J. van Scharrenburg, A. M. Palache, et al. 2001. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coll heat-labile toxin induces IgA-or IgG-mediated protective mucosal immunity. Vaccine 19:2898-2907.
26. Hajishengallis, G., S. Arce, C. M. Gockel, T. D. Connell, and M. W. Russell. 2005. Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections. J. Dent. Res. 84: 1104-1116.
27. Harper, S. A., K. Fukuda, N. J. Cox, and C. B. Bridges. 2003. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 52(RR-13):1-8.
28. Hierholzer, J. C., and M. T. Suggs. 1969. Standardized viral hemagglutina-tion and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions. Appl. Microbiol. 18:816-823.
29. Lamm, M. E., J. G. Nedrud, C. S. Kaetzel, and M. B. Mazanec. 1995. IgA and mucosal defense. APMIS 103:241-246.
30. Lee, M. S., and C. F. Yang. 2003. Cross-reactive H1N1 antibodyresponses to a live attenuated influenza vaccine in children: implication for selection of vaccine strains. J. Infect. Dis. 188:1362-1366.
31. Lycke, N., and W. Strober. 1989. Cholera toxin promotes B-cell isotype differentiation. J. Immunol. 142:3781-3787.
32. Mazanec, M. B., J. G. Nedrud, C. S. Kaetzel, and M. E. Lamm. 1993. A three-tiered view of the role of IgA in mucosal defense. Immunol. Today 14:430-435.
33. McCluskie, M. J., and A. M. Krieg. 2006. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr. Top. Microbiol. Immunol. 311:155-178.
34. Mendelman, P. M., R. Rappaport, I. Cho, S. Block, W. Gruber, M. August, et al. 2004. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J. 23:1053-1055.
35. Mota, G., M. Manciulea, E. Cosma, I. Popescu, M. Hirt, E. Jensen-Jarolim, et al. 2003. Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur. J. Immunol. 33:2197-2205.
36. Murphy, B. R., D. L. Nelson, P. F. Wright, E. L. Tierney, M. A. Phelan, and R. M. Chanock. 1982. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect. Immun. 36:1102-1108.
37. Oh, Y., K. Ohta, H. Kuno-Sakai, R. Kim, and M. Kimura. 1992. Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine. Vaccine 10:506-511.
38. Peppoloni, S., P. Ruggiero, M. Contorni, M. Morandi, M. Pizza, R. Rappuoli, et al. 2003. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2:285-293.
39. Pierre, P., O. Denis, H. Bazin, E. Mbongolo Mbella, and J. P. Vaerman. 1992. Modulation of oral tolerance to ovalbumin by cholera toxin and its B subunit. Eur. J. Immunol. 22:3179-3182.
40. Plante, M., T. Jones, F. Allard, K. Torossian, J. Gauthier, N. St-Felix, et al. 2001. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 20:218-225.
41. Ramphal, R., R. C. Cogliano, J. W. Shands, Jr., and P. A. Small, Jr. 1979. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect. Immun. 25:992-997.
42. Renauld, J. C. 2001. Newinsights into the role ofcytokines inasthma. J. Clin. Pathol. 54:577-589.
43. Renegar, K. B., and P. A. Small, Jr. 1991. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 65:2146-2148.
44. Renegar, K. B., P. A. Small, Jr., L. G. Boykins, and P. F. Wright. 2004. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173:1978-1986.
45. Riddiough, M. A., J. E. Sisk, and J. C. Bell. 1983. Influenza vaccination. JAMA 249:3189-3195.
46. Ryan, E. J., E. McNeela, G. A. Murphy, H. Stewart, D. O'Hagan, M. Pizza, et al. 1999. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67:6270-6280.
47. Ryan, E. J., E. McNeela, M. Pizza, R. Rappuoli, L. O'Neill, and K. H. Mills. 2000. Modulation of innate and acquired immune responses by Escherichia coll heat-labile toxin: distinct pro-and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J. Immunol. 165:5750-5759.
48. Soenawan, E., I. Srivastava, S. Gupta, E. Kan, R. Janani, J. Kazzaz, et al. 2004. Maintenance of long-term immunological memory by low avidity IgMsecreting cells in bone marrow after mucosal immunizations with cholera toxin adjuvant. Vaccine 22:1553-1563.
49. Tamura, S., Y. Ito, H. Asanuma, Y. Hirabayashi, Y. Suzuki, T. Nagamine, et al. 1992. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 149:981-988.
50. Tamura, S. I., Y. Samegai, H. Kurata, K. Kikuta, T. Nagamine, C. Aizawa, et al. 1989. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine 7:257-262.
51. Tamura, S. I., H. Asanuma, Y. Ito, Y. Hirabayashi, Y. Suzuki, T. Nagamine, et al. 1992. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur. J. Immunol. 22:477-481.
52. Tamura, S., T. Tanimoto, and T. Kurata. 2005. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58:195-207.
53. Taylor, J. M., M. E. Ziman, J. Fong, J. V. Solnick, and M. Vajdy. 2007. Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations. Infect. Immun. 75:3462-3469.
54. Tumpey, T. M., M. Renshaw, J. D. Clements, and J. M. Katz. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150.
55. Vajdy, M., B. Baudner, G. Del Giudice, and D. O'Hagan. 2007. A vaccination strategy to enhance mucosal and systemic antibody and T-cell responses against influenza. Clin. Immunol. 123:166-175.
56. Vajdy, M., M. Singh, M. Ugozzoli, M. Briones, E. Soenawan, L. Cuadra, et al. 2003. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 110:86-94.
57. Vajdy, M., M. Singh, J. Kazzaz, E. Soenawan, M. Ugozzoli, F. Zhou, et al. 2004. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res. Hum. Retrovir. 20:1269-1281.
58. Vajdy, M., M. H. Kosco-Vilbois, M. Kopf, G. Kohler, and N. Lycke. 1995. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 181:41-53.
59. Verthelyi, D., and D. M. Klinman. 2003. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol. 109: 64-71.
60. Verweij, W. R., L. de Haan, M. Holtrop, E. Agsteribbe, R. Brands, G. J. van Scharrenburg, et al. 1998. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 16:2069-2076.
61. Wagner, D. K., M. L. Clements, C. B. Reimer, M. Snyder, D. L. Nelson, and B. R. Murphy. 1987. Analysis ofimmunoglobulinG antibodyresponses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol. 25:559-562.
62. Waldman, R. H., S. H. Wood, E. J. Torres, and P. A. Small, Jr. 1970. Influenza antibody response following aerosol administration of inactivated virus. Am. J. Epidemiol. 91:574-585.
63. Williams, A. E., L. Edwards, I. R. Humphreys, R. Snelgrove, A. Rae, R. Rappuoli, et al. 2004. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J. Immunol. 173:7435-7443.
64. World Health Organization. 2005. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353:1374-1385.
65. Zhang, Y., S. Pacheco, C. L. Acuna, K. C. Switzer, Y. Wang, X. Gilmore, et al. 2002. Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus. Immunology 105:286-294.